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METFORMIN: FROM ANTI-DIABETIC TO CANCER THERAPEUTIC 
MICHAEL J. JAVORSKI 
ABSTRACT 
 Epidemiology studies have found that type 2 diabetics treated with metformin are 
at a lower risk for developing cancer.   It was speculated that the lowered risk might be 
attributed metformin’s indirect physiological effect of lowering blood insulin levels, 
which is the opposite of many other antidiabetic drugs.  However, further study of 
metformin’s mechanism of action at the cellular level helped develop an understanding of 
its effect on the individual cell.  This helped show why, mechanistically, it makes sense 
to use metformin for the treatment of cancer.  As an activator of AMP-activated protein 
kinase (AMPK) via inhibition of complex 1 of the mitochondrial electron transport chain, 
metformin causes suppression of tumor growth and cell cycle arrest by acting on the 
mTOR pathway and cyclin/CDKs, respectively. Metformin has been most extensively 
studied in breast cancer, showing great efficacy in numerous breast cancer cell lines that 
include ER positive, HER2 positive, and triple negative breast cancer cell lines.  This 
compilation of data and results of metformin’s efficacy in various cancer subtypes will 
help push metformin forward as a new chemotherapeutic for breast cancer, and 
eventually for other cancer types as well. 
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INTRODUCTION 
 Diabetes is one of the most prevalent diseases in the United States, affecting an 
estimated 25.8 million people, 8.3% of the U.S. population; type 2 diabetes mellitus 
contributes to about 95% of diabetic patients (cdc.gov, 2011).  With its increasing 
prevalence, an association began to emerge between type 2 diabetes mellitus (T2DM) and 
cancer.  This would be an important correlation since cancer is the cause of 8.2 million 
deaths worldwide, and has placed among heart disease as one of the top causes of death 
(who.int, 2014).  The study of cancer in the context of diabetes is therefore extremely 
relevant, and is the reason why much focus has been given to this area of interest.  Many 
researchers have found statistical significance showing that T2DM patients, especially if 
untreated, have a greater chance of developing cancer. 
 An assessment of the current treatments for T2DM has shown that only one drug, 
metformin, decreases the risk for cancer relative to the other drugs.  Metformin is widely 
used and a top choice for the treatment of T2DM, and may now receive even greater 
attention and usage for its potential anti-cancer properties.  In order to understand the 
drug more clearly, researchers have still been trying to elucidate its precise mechanism in 
the treatment of T2DM.  Now that the drug has shown potential for the use in cancer, 
researchers are reexamining the mechanism of its action.  However, this time they are 
looking at how metformin affects cell growth and proliferation.  Knowledge of the 
precise mechanisms of its antineoplastic effects will help move this drug into clinical 
trials and maybe some day as a new standard of treatment all other chemotherapeutics for 
cancer. 
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Correlation between Diabetes and Cancer 
 As Giovannucci et al. summarized in a consensus report, the relative risk from 
diabetes is at least 2-fold or more for liver, pancreatic, and endometrial cancers, while the 
relative risk is moderate for cancer of the colon, rectum, breast, and bladder (Giovannucci 
et al., 2010).  Luo et al. calculated in a meta-analysis that individuals with T2DM have a 
significant increase in risk of developing colorectal cancer, with a relative risk of 1.28 
(Luo et al.,  2012).  Another meta-analysis showed that women with T2DM have an 
increased risk for breast cancer by 27% (Boyle et al., 2012).  On the contrary, T2DM 
patients were actually shown to have a lowered risk of prostate cancer than those without 
diabetes (Giovannucci et al., 2010).  There are a significant number of studies on 
common cancers; however, one of the areas lacking in the literature is the risk that 
patients with T2DM have for the less common cancers. 
 In regards to mortality rate instead of incidence of cancer, T2DM patients 
diagnosed with cancer also have an increased long term mortality rate (Barone et al., 
2008). One meta-analysis showed that T2DM patients had an increased mortality hazard 
ratio of 1.41, when compared to non diabetic patients across all types of cancer (Barone 
et al., 2008). The most statistically significant correlations for an increased mortality rate 
among diabetics compared to non-diabetics were observed in those with cancers of the 
endometrium, breast, and colorectum, with hazard ratios of 1.76, 1.61, and 1.32, 
respectively (Barone et al., 2008).  Another study found that patients with pre-existing 
T2DM are associated with higher rates of prostate cancer mortality and all cause 
mortality, even though the previously mentioned study showed that the incidence of 
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prostate cancer was lower for T2DM patients (Bensimon et al.,  2014; Giovannucci et al., 
2010).  All cause mortality is referring simply to the death rate from any cause.  So an 
increased all cause mortality rate for T2DM patients means that they have generally an 
increased death rate when compared to the rest of the population, and are more likely to 
live a shorter life. 
 To sum up the data presented so far, patients with preexisting T2DM have 
increased incidence of liver, pancreatic, endometrial, colon, rectum, breast, and bladder 
cancer (Giovannucci et al., 2010).  T2DM patients with certain cancers are also shown to 
have an increased mortality rate when compared to non diabetic patients with the same 
cancer (Barone et al., 2008). These observations show significant correlation between 
type 2 diabetes mellitus and many types of cancer, so there probably is some 
physiological or biochemical link(s) between the two.  Exposing the links or common 
risk factors between T2DM and cancer may aid in the development of treatment or 
preventative measures. 
 
Diabetic Characteristics Posing a Risk to Cancer 
Patients with T2DM may be at a greater risk of neoplastic growth because of 
some of the physiologic characteristics of the disease, such as hyperinsulinemia, 
hyperglycemia, and chronic inflammation (Giovannucci et al., 2010).  T2DM, also 
known as noninsulin-dependent diabetes mellitus, is a disease in which the body has 
become insulin insensitive (Kemp et al., 2008).  Due to consistently high levels of blood 
glucose, the body constantly demands output of insulin from the pancreas.  If this state 
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becomes chronic, then the body’s cells become desensitized and down-regulate the 
insulin receptors that are displayed on the surface of cells.  These insulin receptors, most 
importantly on the muscle cells and adipocytes, promote taking up glucose from the 
blood, thereby lowering the blood glucose levels to normal.  If the insulin receptors are 
down-regulated, as occurs with T2DM, then the mechanism of lowering blood glucose 
becomes ineffective, and therefore requires more and more insulin to achieve a normal 
blood glucose level.  Eventually the pancreas will reach a limit on the amount of insulin it 
can produce, and therefore will not be able to lower the glucose levels, leaving the 
individual in a state termed metabolic syndrome.   The chronic hyperglycemia, increased 
blood pressure, and other conditions of metabolic syndrome can lead to many 
microvascular and macrovascular disease states, such as atherosclerosis, retinopathy, 
nephropathy, and peripheral neuropathy (Kemp et al. 2008).  The T2DM characteristics, 
hyperinsulinemia, hyperglycemia, and chronic inflammation, are known to be important 
factors causing these disease states. However, these characteristics have only been 
suggested and not yet confirmed to be the reason for the higher risk of cancer incidence 
and mortality in T2DM patients. 
 
Hyperinsulinemia 
 Firstly, hyperinsulinemia, a state of elevated insulin levels, may induce growth in 
neoplastic tissues via binding to insulin-like growth factor 1 receptors (IGF1-Rs).  The 
primary ligand for IGF1-R is of course insulin-like growth factor 1 (IGF1); however, 
insulin is also capable of binding to this receptor, albeit with a lower affinity than IGF1 
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(National Library of Medicine (US), 2014).  It has been observed that many cancer cell 
lines display IGF1-Rs and thus experience potentiated growth when exposed to IGF1 
(Pollak, 2008).  Recent studies have also shown that the insulin receptor is also 
commonly expressed, and sometimes overexpressed on human neoplastic cells (Cox et 
al., 2009; Frasca et al., 2008).  The prostate is not usually responsive to insulin since it 
does not normally express IGF1-R; however, it was found that human prostate cancer 
cells express such receptors (Cox et al., 2009).  Furthermore, subunits of the IGF1-R and 
the insulin receptor are capable of forming a hybrid receptor, which could in part explain 
the hypothesis of an insulin mediated IGF1 receptor signaling response (Frasca et al., 
2008).  Another explanation could simply be that the elevated levels of insulin help 
overcome the low affinity of insulin for the IGF1-R, causing aberrant activation.   
 Secondly, hypersinsulinemia may contribute to increased neoplastic growth via 
insulin receptor activation (Pollak, 2008).  The insulin receptor contributes mainly to 
metabolic signaling, for example by inserting GLUT4 into the plasma membrane so that 
the cell can uptake more glucose for cell anabolism and for energy production (Frasca et 
al., 2008).  A fact that may be overlooked is that the insulin receptor is also part of a 
growth signaling pathway, through the activation of Ras and Akt (Frasca et al., 2008).  
Thus the insulin receptor alone may be a key modulator in cancer progression. 
 Thirdly, elevated levels of insulin may change the levels of free circulating 
hormones and growth factors in the blood (Giovannucci et al., 2010; Pasanisi et al., 
2006).  Hyperinsulinemia has an effect on the liver which reduces the amount of IGF 
binding protein produced (Giovannucci et al., 2010).  A lower level of IGF binding 
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protein would cause less IGF-1 to be bound in the blood and more to be circulating 
freely, therefore allowing more IGF-1 to act on its target sites.  In a study of 110 
postmenopausal women with breast cancer, the women with metabolic syndrome showed 
significantly higher levels of testosterone and estradiol, and significantly lower levels of 
the sex hormone-binding globulin (SHBG) when compared to the women without 
metabolic syndrome (Pasanisi et al., 2006).  The increased production and higher levels 
of circulating sex steroids has been linked to a higher rate of cancer recurrences in these 
women, and may have important mitogenic factors in other cancers as well (Pasanisi et 
al., 2006). 
  
 Hyperglycemia 
Hyperglycemia seems like it would be a formidable risk factor for neoplastic 
growth; however, most cancer cells already have a highly up-regulated insulin-
independent uptake of glucose (Giovannucci et al., 2010). This highly up-regulated 
glucose uptake by cancer cells is exploited by FDG-PET scanning for tumors, which uses 
a radioactive glucose analogue that should be rapidly taken up the cancer cells (Cornett & 
Dea, 2014).  Chronic elevated blood glucose levels should only give the cancer cells a 
slight advantage since the cancer cells are already obtaining rapid rates of glucose uptake 
(Giovannucci et al., 2010).  The only major advantage that hyperglycemia provides for 
neoplastic growth might be that it causes elevated levels of insulin.  
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 Obesity and Inflammation 
Obesity is a very common characteristic associated with T2DM, and may also be 
a risk factor for cancer.  White adipose tissue is considered to be an endocrine organ, and 
in the case of obesity, it releases elevated levels of inflammatory cytokines which may 
have tumorigenic capabilities (Giovannucci et al., 2010).  Some of these cytokines, like 
plasminogen activator inhibitor-1, have been associated with a worse prognosis for 
women with breast cancer (Giovannucci et al., 2010).  Interleukin-6 is another cytokine 
which is known to promote tumor proliferation and invasion (Giovannucci et al., 2010).   
 It is clear that there are multiple characteristics of T2DM that may pose a risk to 
the development and progression of cancer.  There are several current drug therapeutics 
to help control the most dangerous risk of T2DM, which is hyperglycemia.  However 
these drugs have different means of lowering the blood glucose to a safe level.  It is 
further being revealed that these different drugs may have different effects on cancer 
prevention and risk. 
 
Current Therapeutics for T2DM 
 Most of the treatments for T2DM are not treatments that cures the disease, but 
rather  help manage it.  The primary concern with the treatment of T2DM is to control of 
the blood glucose levels. Some of the classes of antidiabetic drug are the sulfonylureas, 
biguanides, thiazolidinediones (TZDs), and insulin replacements (Nolte Kennedy, 2012).  
The sulfonylureas, also known as insulin secretagogues, have a primary action of 
promoting the release of insulin from the pancreas (Nolte Kennedy, 2012).  The 
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biguanides, like metformin, have a primary effect on the liver by reducing the hepatic 
glucose production (Nolte Kennedy, 2012).  Other minor mechanisms of action of 
biguanides include stimulation of glycolysis in tissues, decreased absorption of glucose 
from the intestines, and enhanced removal of glucose from the blood by increasing the 
sensitivity of tissues to insulin (Nolte Kennedy, 2012).  The main mechanism of action of 
TZDs is to decrease insulin resistance, which would therefore increase the glucose uptake 
into tissues like adipocytes and muscles, and lower blood glucose levels (Nolte Kennedy, 
2012).  Lastly, insulin replacement therapy, which is the major treatment for type 1 
diabetes mellitus, can be used in T2DM if the patient’s pancreatic cells are burned out 
from constant secretion of insulin (Nolte Kennedy, 2012).  The exogenous insulin would 
act just like the endogenous insulin by lowering blood glucose levels. 
 With the increasing prevalence of T2DM and the use of various types of 
antidiabetic drugs, many groups of researchers have gathered information from larger 
subject groups in order to compare the outcomes, effectiveness, and side effects of these 
different drug classes.  Many studies have recently found relationships between these 
drugs and cancer risk.  A meta-analysis of primary studies looking at the effects of 
metformin and sulfonylureas in patients with T2DM concluded that the use of metformin 
is associated with a reduction of cancer risk, considering all cancer sites (Thakkar et al., 
2013).  This same meta-analysis also concluded that the use of sulfonylureas in patients 
with T2DM is associated with an increased cancer risk, considering all cancer sites 
(Thakkar et al., 2013).  A different meta-analysis assessed the risk of hepatocellular 
carcinoma (HCC) with respect to the use of metformin, TZDs, sulfonylureas, and insulin 
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in T2DM patients (Singh et al., 2013).  Statistically significant data reported that 
metformin use in T2DM patients confers a 50% reduction of HCC incidence (Singh et 
tal., 2013).  Sulfonylurea use in T2DM was shown to increase HCC incidence by 62%, 
while insulin use in T2DM was shown to increase HCC incidence by 161% (Singh et al.,  
2013).  The use of TZDs in T2DM patients did not show any statistically significant 
reduction or increase in HCC incidence (Singh et al., 2013).  A third meta-analysis 
looking at the relationship between the various antidiabetic drugs and colorectal cancer 
observed that metformin use is associated with a statistically significant 11% reduction in 
colorectal cancer risk (Singh et al., 2013). In this study, TZD use was not shown to affect 
the risk of colorectal cancer (Singh et al., 2013).  Use of sulfonylureas and insulin were 
observed to confer a higher risk of colorectal cancer; however, these data were not 
statistically significant (Singh et al., 2013).  From these three studies, the biguanide, 
metformin, is the only antidiabetic drug to show statistically significant associations with 
a decreased risk of cancer at multiple tissue sites in T2DM patients.  Therefore, it is 
reasonable to assume that metformin may have a cancer protective effect in T2DM 
patients, and perhaps in non-diabetic patients. 
Various other large-scale studies on metformin use in T2DM patients reveal 
further evidence of its role in reducing cancer risk.  A meta-analysis was conducted to 
determine the previously disputed relationship between metformin use for T2DM and 
breast cancer incidence (Col et al., 2012).  Drawing from four cohort studies and three 
case control studies, this meta-analysis calculated an odds ratio of 0.83 for metformin use 
and breast cancer incidence (Col et al., 2012).  Due to the large number of patients 
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assessed in this meta-analysis, the data are statistically significant and suggest that 
metformin does indeed have a protective effect on breast cancer in women with T2DM 
(Col et al., 2012).  To further drive home the point, another meta-analysis focused on the 
relationship between metformin use in T2DM patients and the risk of colorectal cancer 
(Zhang et al., 2011).  After considering three cohort studies and two case-control studies, 
patients with T2DM treated with metformin compared to T2DM patients on other 
treatment were associated with a relative risk of 0.63 for developing colorectal cancer 
(Zhang et al., 2011).   
There seems to be an overall association between metformin use and lower 
incidence of cancer in T2DM patients.  However, before going into the proposed cancer-
protective mechanisms of the drug metformin, its basic role in the treatment of T2DM 
and its molecular mechanism of action will be presented. 
 
Metformin 
 Metformin belongs to the biguanide class of antidiabetic drugs and is the first 
choice of treatment for T2DM (Nolte Kennedy, 2012).  From a clinical standpoint, it 
lowers basal and postprandial blood glucose levels; however, it does not stimulate 
endogenous insulin secretion or mimic insulin like some of the other antidiabetic drug 
classes (Gong et al., 2012).  This gives metformin a higher level of safety compared to 
some other classes of antidiabetic drugs since it is less likely to cause hyperinsulinemia 
and hypoglycemia (Gong et al., 2012).  The major mechanism of action, as previously 
stated, is the reduction of gluconeogenesis and release of glucose from the liver (Nolte 
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Kennedy, 2012). Metformin is also known as an insulin sensitizer, which comes from its 
ability to increase the sensitivity of peripheral tissues to insulin, thus increasing the 
glucose uptake and lowering blood glucose levels (Gong et al., 2012).   Metformin is also 
thought to have other minor effects such as a reduction of intestinal glucose absorption, 
reduction of fatty acid and triacylglycerol synthesis, stimulation of glycolysis in 
peripheral tissues, elevation of the conversion of glucose to lactate in enterocytes, and 
reduction of glucagon levels (Gong et al., 2012; Nolte Kennedy, 2012).  Due to all of the 
mentioned mechanisms of metformin, it is a very effective drug for lowering blood 
glucose levels and therefore a top choice of treatment for T2DM.   
 From this information, there are several plausible basic explanations as to how 
metformin lowers cancer risk in T2DM patients.  First of all metformin helps control 
blood glucose levels, although unlike most other antidiabetic drugs, it does not act by 
further increasing insulin levels.  As previously stated, hyperinsulinemia is one of the 
potential diabetic characteristics thought to increase the cancer risk in T2DM patients.  
Metformin increases the responsiveness of peripheral tissues to insulin, which would 
enable lower levels of insulin to have the same glucose lowering effect compared to the 
previously higher levels.  Hence, metformin should lower the elevated insulin levels 
which should therefore lower the physiological responses to hyperinsulinemia, which 
include spill over of insulin onto IGF1-R, overstimulation of cancer cells expressing high 
levels of insulin receptors, reduction of plasma binding proteins which increases the 
concentration of free hormones, and elevation of sex steroids (Frasca et al., 2008; 
Giovannucci et al., 2010; Pollak, 2008).  The other antidiabetic drugs, like the 
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sulfonylureas and the insulin replacement proteins also lower blood glucose levels, but 
the problem is that they contribute to higher insulin levels, which exacerbates the 
neoplastic promoting conditions of hyperinsulinemia.  
 The main mechanism of metformin, which is the reduction of hepatic glucose 
output, also helps to maintain lower blood glucose levels; however, as previously 
mentioned, it may not have any significant effect on neoplastic growth, given that cancer 
cells already have a high uptake of glucose from insulin-independent mechanisms 
(Giovannucci et al., 2010).  The only benefit of reduced hepatic glucose output for cancer 
protection is that the pancreatic beta cells would receive less stimulation to increase 
insulin levels.  Lastly, metformin is not typically known to increase weight gain, as 
opposed to the sulfonylureas, and therefore would not exacerbate the inflammatory 
cytokine signaling from adipose tissue (Nolte Kennedy, 2012). 
Metformin may indeed reduce cancer risk through these mechanisms; however, 
these are only macroscopic mechanisms looking at the big physiological picture.  Data on 
metformin’s precise molecular mechanism of action have been studied extensively over 
the last 10 to 15 years.  A general consensus has been reached on some of the precise 
mechanisms and pathways that metformin activates; however, new data continue to be 
published.  The following data are some important studies that have led to the elucidation 
of metformin’s major mechanism of action on a cellular level.  The study of metformin’s 
effects on the molecular level will help determine what other effects it has on cancer 
prevention besides its influence on insulin levels. 
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Molecular Mechanism of Action  
Previous studies have shown some controversy on the precise mechanism of action of 
the drug metformin.  Metformin’s effect on circulating glucose and lipids was known, but 
there was no record of a precise mechanism. In 2000, El-Mir et al. and Owen et al. both 
conducted experiments in rat hepatocytes that showed metformin inhibits complex 1 of 
the mitochondrial electron transport chain, which causes the levels of ATP to change (El-
Mir et al., 2000; Owen et al., 2000).  In 2001, Zhou et al. were the first to show that the 
action of metformin works through an AMPK dependent pathway, which makes sense in 
light of the evidence that it changes the ATP levels (Zhou et al., 2001).  Many studies 
were published thereafter and have either supported or refuted these proposed 
mechanisms of action.  Some of these studies will be looked at closely in order to 
determine the true mechanism of action of metformin.  Most of these studies revolve 
around a very important protein called AMP-activated protein kinase (AMPK).  
AMPK is a major energy status regulatory protein that detects changes in adenine 
nucleotide levels, as seen in Figure 1 (Hardie, 2007).  It is a heterotrimer composed of α, 
β, and γ subunits; the α subunit is the catalytic subunit and the β and γ subunits are the 
regulatory units (Hawley et al., 2010). With lower levels of ATP, and hence a higher  
ADP/ATP ratio, the AMP/ATP ratio also increases due to the conversion of ADP into 
ATP and 1AMP (Hawley et al., 2010).  AMP levels are usually extremely low so a 1:1 
ratio in the increase of ATP and AMP still results in an increased ratio of total 
AMP/ATP.   The rising AMP levels bind AMPK, and stimulate the phosphorylated form 
of AMPK, which is the active form (Hardie, 2007).  The binding of AMP also inhibits the 
!14 
dephosphorylation of AMPK, which keeps it active for a longer period of time (Hardie, 
2007).  The AMPK is initially activated via phosphorylation by several upstream kinases; 
however, the action of AMP is to further stimulate AMPK and keep it activated (Hardie, 
2007; Hawley et al., 2010).  Once AMPK is activated it phosphorylates key enzymes 
involved in metabolism that switches the cell from an anabolic to a catabolic state 
(Hardie, 2007).  Therefore, the synthesis of lipids, glucose, proteins, and even cell growth 
Figure'1:'Role'of'AMPK'in'cellular'catabolism'and'anabolism.''Many!stressors,!like!metformin,!cause!a!reduction!in!ATP!production,!which!unleash!the!inhibitor!affect!on!AMPK.!!The!buildup!of!ADP!and!AMP!act!to!activate!AMPK.!!AMPK!!turns!off!the!cellular!processes!involved!with!ATP!consumption,!like!cell!division!and!growth.!!!Figure!taken!from!(Hardie,!2007).!
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is down-regulated, and fatty acid oxidation and glucose uptake are up-regulated (Hardie, 
2007).  
 
Inhibition of Complex 1 of the ETC  
 El-Mir et al. was the first study to show that metformin hinders cellular 
respiration by its inhibitory effect on complex 1 of the electron transport chain (ETC) of 
the mitochondria (El-Mir et al., 2000).  Complex 1 is one of the multiple units of the ETC 
in the mitochondria, which helps create an electrochemical gradient between the matrix 
and interstitial space of the mitochondria.  This electrochemical gradient drives protons 
through an ATPase in the inner mitochondrial membrane, which converts ADP into ATP, 
a source of energy for the cell.  By inhibiting complex 1 of the ETC, the proton pumps 
are less active and therefore the electrochemical gradient becomes weaker and less 
capable of driving the synthesis of ATP through the ATPase (Janson, 2014). 
 El-mir et al. observed no inhibition of complex 1 when isolated mitochondria 
were treated with metformin, which strongly suggests that metformin has no direct effect 
on complex 1 (El-Mir et al., 2000). Direct ETC inhibitors like rotenone and cyanide 
inhibit cellular respiration, and would show decreased cellular respiration when incubated 
with isolated mitochondria; however, metformin is different from these direct inhibitors 
(Janson, 2014).  Inhibition of complex 1 was observed in intact hepatocytes treated with 
metformin, which would suggest that metformin works indirectly to inhibit complex 1 via 
some cellular pathway that has yet to be established (El-Mir et al., 2000).  Data showing 
the inhibition of cellular respiration in rat hepatocytes with treatment of metformin 
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(dimethylbiguanide) can be seen in Table 1 (El-Mir et al., 2000).  After 30 minutes of 
incubation with metformin, the following parameters were determined: cellular 
respiratory rate (JO2), in situ mitochondrial membrane potential (ΔΨ), cytosolic and 
mitochondrial ATP/ADP ratios, ratio of lactate to pyruvate, and ratio of 3-
hydroxybutyrate to acetoacetate (El-Mir et al., 2000). When compared to the control 
group, the hepatocytes treated with dimethylbiguanide, or metformin, showed a 
significant decrease in mitochondrial membrane potential (ΔΨ), which is in accordance 
with the decrease in cellular respiratory rate (JO2) (El-Mir et al., 2000).  The ATP/ADP 
ratios of the mitochondrial and cytosol lowered significantly, which would mean that the 
levels of ATP have decreased when compared to ADP levels, explained by the reduced 
mitochondrial membrane potential and reduced production of ATP from the ATP 
synthase (El-Mir et al., 2000).   
In order to determine whether the inhibition resulted from a reduction of energy 
substrates for the ETC or from inhibition of ETC function, the lactate/pyruvate (lac/pyr) 
ratio and 3-hydroxybutyrate/acetoacetate (3-OH/AcAc) ratios were recorded (El-Mir et 
al., 2000).  The lac/pyr ratio reflects cytosolic NADH concentrations, while the 3-
OH/AcAc ratio reflects mitochondrial NADH concentrations; higher ratios, as observed 
in the hepatocytes treated with dimethylbiguanide, are indicative of an increase in energy 
substrates (El-Mir et al., 2000).  This is evidence that the action of dimethylbiguanide, 
metformin, is indeed through inhibition of the ETC machinery involved in cellular 
respiration.  This study had not yet linked this data to the activation of AMPK though. 
17 
!
!
 
  
 
 
 
 
 
 
 
Table 1. Effects of dimethylbiguanide, myxothiazol, and rotenone on cellular respiratory function.  
Intact rat hepatocytes were incubated with no inhibitors, 10 mM dimethylbiguanide, .15 µM myxothiazol, 
or .52 µM rotenone.  After 30 minutes of incubation, cellular respiratory rate (JO2), in situ mitochondrial 
membrane potential (ΔΨ), cytosolic and mitochondrial ATP/ADP ratios, ratio of lactate to pyruvate 
(lac/pyr), and ratio of 3-hydroxybutyrate to acetoacetate (3-OH/AcAc) were recorded. Table taken from 
(El-Mir et al, 2000). !
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 Since the publication of this study by El-Mir et al. in 2000, various other 
researchers have published studies on metformin and its mechanism of action.  Owen et 
al. published a study also in 2000, which showed further evidence that metformin inhibits 
complex 1 of the ETC, albeit they showed that metformin acted directly on the 
mitochondria, instead of indirectly through an undetermined signaling pathway as El-Mir 
et al. suggested (El-Mir et al., 2000; Owen et al., 2000).  Although these two studies 
differ in the proposed inhibition of complex 1, they still nonetheless gave evidence that 
complex 1 is indeed inhibited by metformin and results in a reduced ratio of ATP/ADP 
(El-Mir et al., 2000; Owen et al., 2000).  An important finding in the study by Owen et al. 
was that although the total nucleotide concentrations were the same, the calculated free 
ATP/ADP ratio was reduced (Owen et al., 2000).  Owen et al. went on to explain that the 
decreased ATP/ADP ratio causes inhibition of pyruvate carboxylase, and the observed 
increase in the concentration of phosphoenolpyruvate leads to a stimulation of pyruvate 
kinase; together these effects lead to a decline in gluconeogenesis, a well known 
characteristic of metformin (Owen et al., 2000).  
  
Metformin and AMPK 
In 2001, Zhou et al. were the first ones to show that metformin acts through an 
AMPK dependent pathway (Zhou et al., 2001).  They gave metformin to a rat hepatocyte 
control cell culture, and then to a rat hepatocyte cell culture with an AMPK inhibitor, 
termed compound C (Zhou et al., 2001). A known AMPK activator, AICAR, was also 
used in another set of cells in place of metformin in order to compare it to metformin’s 
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stimulation of AMPK (Zhou et al., 2001).  The control group treated with metformin or 
AICAR showed a decrease in glucose output and acetyl-CoA carboxylase (ACC) activity 
(Zhou et al., 2001).  ACC is a classic AMPK substrate target.  The rat hepatocytes given 
both the AMPK inhibitor and metformin/AICAR showed a reduction of metformin’s 
effects, which was observed as a lesser reduction of glucose output and less inhibition of 
ACC (Zhou et al., 2001). 
As shown in Figure 2, when metformin or the AMPK activator, AICAR, were 
given alone there was a significant reduction in ACC activity (Zhou et al., 2001)  Once 
the AMPK inhibitor compound C was added to either cell culture,  an increasing ACC 
activity was associated with an increasing dose of the AMPK inhibitor while the dose of 
metformin/AICAR was held constant (Zhou et al., 2001).  Given that an activated AMPK 
inhibits ACC activity, a deactivated AMPK should not be able to inhibit ACC, which 
increases ACC activity.  These results therefore showed that metformin requires the 
activation of AMPK in order to display its effect in lowering hepatic glucose production 
(Zhou et al., 2001).  However, the mechanism of AMPK activation was unclear; it was 
not known if this was a direct activation or due to a complex signaling pathway. 
!20 
 
After these initial studies, it seemed that metformin worked by causing changes in 
cellular adenine nucleotide levels that affect AMPK.  However other researchers 
postulated that metformin activates AMPK without changing the ratio of AMP to ATP, 
which refutes both studies performed by El-Mir et al. and Owen et al. (Hawley et al.,  
2002).  Another study observed that an upstream kinase, LKB1, was the major activating 
kinase of AMPK from metformin use (Shaw et al., 2005).  Later, Hardie reported that 
metformin’s role of reducing hepatic glucose output was not due to direct activation of 
LKB1 or AMPK by metformin (Hardie, 2006).  LKB1 is indeed required for AMPK 
activation, but it is not altered by metformin (Hardie, 2006)  Still more proposed 
mechanisms were published.  Fujita et al. reported that metformin did not increase the 
AMP/ATP ratio in their mouse hepatocytes; however, it did generate peroxynitrite, a 
Figure'2:'Use'of'an'AMPK'inhibitor'to'show'that'metformin'works'through'
AMPK'dependent'pathways.'!In!vitro!rat!hepatocytes!were!treated!with!metformin!or!AICAR,!a!direct!AMPK!activator.!!AcetylBCoA!carboxylase!(ACC)!activity!was!measured!at!varying!concentrations!of!compound!C,!the!AMPK!inhibitor.!!!! ! ! ! Figure!amended!from!(Zhou!et!al,!2001).!
!
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reactive nitrogen species, which they suspected to activate AMPK (Fujita et al., 2010).  
The fact of the matter is that there are multiple ways to activate AMPK, being that it is 
the center of many metabolic signaling pathways (Hawley et al., 2010).  The goal is to 
determine which are the main pathways involved with the use of metformin.   
 Stephenne et al. sought out to test the previous studies but in human hepatocytes, 
and to hopefully make a clear determination as to the correct mechanism of action of the 
drug metformin (Stephenne et al., 2011).  They tested the hypothesis that metformin 
activates AMPK through an increase in AMP concentration resulting from the inhibition 
of the mitochondrial complex 1 (Stephenne et al., 2011).   In rat hepatocytes, metformin 
increased AMP levels and AMPK activation (Stephenne et al., 2011). In human 
hepatocytes, metformin also increased AMP levels and AMPK activation as seen in 
Figure 3 a & b (Stephenne et al., 2011).  
 An interesting finding was that the same increase seen in AMP levels in humans 
caused a greater response of the human AMPK (Stephenne et al., 2011).  This led the 
authors to search for isoforms of AMPK, finding that humans mainly expressed 
AMPKα1, but rats express both AMPKα1 and AMPKα2 at similar concentrations 
(Stephenne et al., 2011).  A difference in affinity of these isoforms of AMPK most likely 
accounts for the greater response seen in humans.  The difference between metformin’s 
effect in rats and humans is important to keep in mind when determining potential 
clinical efficacy. 
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 Next the link between AMPK and the cellular energy levels in metformin 
treatment was explored using knockouts of liver specific AMPKα1 and 2 from mice 
(Stephenne et al., 2011).  In the wild type mice, metformin increased the level of AMP 
and increased the activation of AMPK; however, the knockout AMPKα1/2 mice showed 
increased levels of AMP with no observable expression of AMPKα1/2, shown in Figure 
4 (Stephenne et al., 2011).  This shows that the inhibition of mitochondrial complex 1 and 
subsequent increase in AMP was not due to AMPK activation, therefore eliminating the 
possibility that metformin directly activates AMPK (Stephenne et al., 2011).   
Figure'3:'Effects'of'metformin'on'AMPK'activity'and'AMP/ATP'ratio'in'
human'hepatocytes.!AMPK!activity!is!measured!in!a,!and!the!AMP/ATP!ratio!is!measured!in!b.!!! ! Figure!amended!from!(Stephenne!et!al.,!2011).!
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 With the experimentation on rat and human hepatocytes, Stephenne et al. came to 
the conclusion that metformin does indeed work through AMPK; however, they ruled out 
the possibility of direct activation of AMPK by metformin (Stephenne et al., 2011).  They 
showed that AMPK is activated from a decrease in ATP and concurrent increase in AMP 
which is due to the inhibition of complex 1 of the mitochondrial respiratory complex 
(Stephenne et al., 2011).   
Why was it so important to determine the precise mechanism of action? The 
target of the drug metformin will help assess whether or not metformin has an effect on 
neoplastic growth and tumorigenesis.  Since it is now generally accepted that metformin 
leads to the activation of AMPK, and since metformin has been statistically shown to 
reduce cancer risk in patients with T2DM, it is justified to look at how the activation of 
!
Figure'4:'Measure'of'AMP/ATP'ratios.''Wild!type!mice!and!AMPKα1/2!Knockout!mice!(AMPKα1/2B/B)!hepatocytes!were!treated!with!metformin!and!the!measured!for!changes!in!AMP/ATP!ratios.!!Black!is!the!control!and!white!is!the!use!of!metformin.!Figure!amended!from!(Stephenne!et!al.,!2011).!
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AMPK affects tumor cancer progression.  Although AMPK may not be the only target 
for metformin, it is one of the most significant and commonly reported.  Therefore, most 
of the antineoplastic effects of metformin that will be reviewed will involve the activation 
of AMPK. 
 
 
 !  
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Specific Aims/Objectives  
 The first choice and most prescribed antidiabetic drug, metformin, has statistically 
been shown to lower risk and improve outcome of cancer in many patients with T2DM in 
retrospective studies.  Extensive research on its possible molecular mechanism of action 
has helped shed some light on metformin’s role in not only diabetic therapy, but in its 
role as a potential cancer therapeutic.  Metformin’s indirect physiological effect on 
plasma insulin levels may be a small part of its role as a cancer therapy; however, 
researchers have dug deeper and explored its effect on cancer cells at the molecular level.  
This paper will present some of the major pathways by which metformin inhibits cancer 
growth and tumorigenesis.  This paper will also present studies in which metformin has 
shown potential for use in specific cancer types, with a focus on breast cancer.  Lastly, 
studies of metformin as an adjunctive therapy to current standards of care for specific 
subtypes of breast cancer will be evaluated for their use in the clinical setting. 
Metformin may be of significant value to the field of cancer.  A compilation of 
publications such as this one will give an understanding of where the field is at the 
present time in considering metformin as a cancer therapeutic, and what future directions 
should be explored.  If shown efficacious in clinical trials for breast cancer, metformin 
will be highly sought after for the treatment of other types of cancers as well.  It would 
probably be most useful as an additional therapy to the current regimens of 
chemotherapy. 
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PUBLISHED STUDIES  
Major mechanisms of action of metformin in cancer cells 
 There are several well-studied pathways through which AMPK may reduce or 
halt neoplastic growth.  Many of these pathways have been elucidated with the use of 
breast cancer cell lines, which are currently a major focus for the benefits of metformin.  
One of the pathways by which metformin induces cell cycle arrest was reported by 
Zhuang & Miskimins, and it was shown to work downstream from metformin’s 
activation of AMPK (Zhuang & Miskimins, 2008).  The other pathway also works via 
AMPK and involves the inactivation of the mTOR pathway (Cantrell et al., 2010). 
 
Cell Cycle Arrest via cyclin/CDKs 
 Zhuang & Miskimins tested the effects of metformin on cell cycle arrest on  6 
different breast cancer cell lines and observed growth arrest in 5 of them, which are 
termed: MCF7, T47D, BT20, MDA-MB-474, and MDA-MB-453 (Zhuang & Miskimins, 
2008).  The breast cancer cell line termed MDA-MB-231 was the only one out of the six 
to have unaffected growth from metformin treatment (Zhuang & Miskimins, 2008).   The 
reason why and the importance of this observation will be examined later in this analysis.   
 After the observation of growth arrest in these 5 breast cancer cell lines, the 
pathways were looked at further.  This study used western blot analysis to examine the 
cell cycle regulatory proteins, such as the cyclins, CDKs, and CDK inhibitors (Zhuang & 
Miskimins, 2008).  It was observed that the cyclin D1 expression was significantly lower 
in metformin treated cells than in the control (Zhuang & Miskimins, 2008).  The basic 
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understanding of  cyclin D1 is that it complexes with a CDK like CDK4, and this 
complex is needed for the progression through late G1 phase and into the S phase 
(Schmid & Carson, 2010).  The more complicated verison of this is that the cyclin 
D1/CDK complex contributes to the phosphorylation and inactivation of the tumor 
suppressor pRB (Schmid & Carson, 2010).  This is one mechanism of cyclin D1 that 
Zhuang & Miskimins did not mention; however, they did mention another one of its 
mechanisms from the observation that cyclin D1 is downregulated and that the CDK 
inhibitors p27 and p21 were downregulated (Zhuang & Miskimins, 2008).  They 
proposed that a downregulated cyclin D1 leads to increased levels of CDK inhibitors like 
p27 and p21 (Zhuang & Miskimins, 2008).  Cyclin D1 is involved with the sequestering 
of CDK inhibitors, and so when cyclin D1 is downregulated via AMPK, the CDK 
inhibitors become free and available to inhibit one of their targets, the cyclin E/CDK2 
complex (Zhuang & Miskimins, 2008).  Like the cyclin D/CDK4 complex, this cyclin 
E/CDK2 complex also contributes to the inactivation of the tumor suppressor pRB 
(Schmid & Carson, 2010).  Therefore, since these cyclin/CDK complexes are 
downregulated and inhibited, the cell cannot inactivate the tumor suppressor pRB and the 
cell cycle arrests in G1 phase.   
 This pathway has enormous significance due to the fact that the cyclin Ds  
respond to cellular stress levels and mitogenic signals like Ras (Schmid & Carson, 2010).  
Mitogenic signaling in a cancer cell is often highly upregulated or out of control, but 
metformin would help to counteract this affect.  Theoretically, since cyclin D also 
!28 
responds to cellular stress levels via AMPK, treatment with metformin would help induce 
a state of lower energy levels and thus counteract the stimuli of the mitogenic signals.   
Another important aspect of this mechanism of inhibition is that it works 
independent of p53.  The protein p21 is downstream of p53, so a mutation in p53 would 
not affect the inhibition imposed by metformin (Schmid & Carson, 2010).  Buzzai et al. 
showed that a colon cancer cell line deficient in p53 (p53-/-) were susceptible to 
metformin, and upon treatment showed suppressed tumor growth and increased apoptosis 
(Buzzai et al., 2007).  This is significant and exciting to hear since a mutation in p53 is a 
common mutation that accumulates during tumorigenesis. 
Now getting back to an earlier question, why wasn’t the cell line MDA-MB-231 
sensitive to metformin, even though the other five cell lines were?  The answer was 
looked at closely by the experimenters and they found that this cell line expressed 
significantly lower basal levels of p21 and p27 (Zhuang & Miskimins, 2008)  This is an 
important discovery because it implies that metformin may not be effective in the 
treatment of other cancers which have a low expression of these CDK inhibitors, which is 
characteristic of many cancers (Zhuang & Miskimins, 2008).   
Kobayashi et al. showed that the amount of phosphorylated pRB was reduced in 
an esophageal cancer cell line upon treatment with metformin, which supports the 
mechanism proposed by Zhuang & Miskimins (Kobayashi et al., 2013).  Less 
phosphorylated pRB may indicate increased levels of unphosphorlated pRB, which is the 
form of pRB that causes cell cycle arrest. 
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Growth Inhibition via mTOR 
Another major mechanism by which metformin is proposed to work against 
cancer cells is by the reduction of the mTOR pathway.  The protein mTOR is an effector 
protein of the PI3K family that responds to growth factors, and therefore is important in 
transducing pro-tumorigenic signals (Chabner et al., 2011).  It is common to find an 
aberrant mTOR signaling pathway in cancer cells, mostly likely due to gene 
amplification or activating mutations (Chabner et al., 2011).  
Cantrell et al. studied endometrial cancer cell lines and also observed an increased 
cell cycle arrest in G1 phase and reduced growth upon treatment with metformin 
(Cantrell et al., 2010).  As in the study by Zhuang & Miskimins, they found that after 
treatment with metformin, AMPK was further activated; however, they focused on the 
mTOR signaling pathway (Cantrell et al., 2010).   
Sixteen hours after treatment with metformin in endometrial cancer cell lines, a 
Western blot analysis was used to determine the concentration of phosphorylated S6 (P-
S6), which is a downstream target of mTOR (Cantrell et al., 2010).  Thus the 
concentration of phosphorylated S6 (the activated form) will indicate whether the mTOR 
signaling pathway is up-regulated or down-regulated.  It was observed that with 
increasing concentrations of metformin, the concentration of P-S6 was reduced 
dramatically in both endometrial cancer cell lines (Cantrell et al., 2010).  This finding 
was looked at again by another study, which also was able to show the same decreased 
phosphorylation of protein S6 upon low dose treatment with metformin (Hanna et al., 
2012).  This is evidence that metformin may have an anti-proliferative role in cancer by 
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activation of AMPK and reducing the activation of mTOR.  As mTOR has been a 
common target in many cancer types, metformin may add to the effect of existing mTOR 
inhibitors and thus have a synergistic anti-proliferative effect.  
 
Overview of anti-neoplastic effects 
 The down-regulation of cyclin D1 and the inhibition of the mTOR pathway are 
just a few of the effects of activation of AMPK.  The time and research spent looking into 
the precise mechanisms of these pathways has been invaluable in moving the field of 
cancer therapeutics forward.  Metformin for the treatment of cancer is a growing area of 
interest; however, a lot more time and research will be needed in order to determine its 
usefulness.  Current research is focusing on which types of cancers it is effective in, and 
part of that should be looking at what cancer genotypes would be most susceptible to 
metformin.  Table 2 is a compilation of data from some of the previously mentioned 
studies that proposes the genotypes that may and may not be susceptible to metformin.  
This table is by no means comprehensive of the entire field of cancer; however, it is a 
start and will need to be expanded as research continues to better assess the benefits of 
metformin. 
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Figure 5 from Rattan el al., summarizes some of the main points mentioned thus 
far regarding the mechanism of action of metformin in cancer cells (Rattan et al., 2012).  
In the background section of the paper, the glucose and insulin lowering effects of 
metformin were discussed as one of the probably systemic benefits.  The significance of 
the inhibition of ACC and HMG CoA reductase were not mentioned but play an 
important role in lipid synthesis needed for cellular growth and division (Rattan et al., 
2012).  Lastly the effect on the cell cycle and inhibition of cell growth were discussed 
previously, and these are becoming of increasing importance in future research. 
These are just some of the main and most recognized mechanisms for 
metformin’s effect on cancer.  However, there many other proposed mechanisms, like the 
reduction of hTERT (telomerase reverse transcriptase) mRNA, which is one of the 
mechanisms of keeping cancer cells immortal (Hanna et al., 2012). 
 
 Publications 
 
Cancer genotype Effective w/ 
metformin  
Vehicle of study 
Buzzai et al., 2007 p53 deficient (p53-/-
) 
Yes Human colon cancer 
xenograft in mice 
Zhuang & 
Miskimins, 2008 
P21 or p27 deficient No Human breast cancer 
in vitro 
My speculation 
from Zhuang & 
Miskimins, 2008 
pRB inactivating 
mutation 
No -  
Cantrell et al., 
2010 
mTOR up-regulated Yes Human endometrial 
cancer in vitro 
Table'2:'Efficacy'of'metformin'in'certain'cancer'genotypes.''Efficacy!with!metformin!is!categorized!as!“Yes”!only!if!there!is!some!antiBneoplastic!effect!observed.!The!table!was!made!using!the!data!from!multiple!studies:!(Buzzai!et!al,!2007)(Zhuang!&!Miskimins,!2008)(Cantrell!et!al.,!2010)!
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 Preclinical/Clinical Studies  
Many of the mechanisms presented are through AMPK in individual cells, and 
not the result of metformin’s insulin and glucose lowering effects. Therefore, most of 
metformin’s effects are through insulin independent pathways, and it has potential for use 
in non-diabetic patients.  Since metformin does not raise insulin levels like other 
antidiabetic drugs, it is safe to use in patients with normal levels of insulin because it will 
not usually cause hypoglycemia (Gong et al., 2012).  Metformin is currently being 
studied alone for its effect on some cancers in non-diabetic patients, and is also being 
Figure'5:'Molecular'Effects'of'Metformin'on'Tumor'Growth.'Note!that!metformin!does!not!directly!activate!LKB1.!!The!picture!is!just!indicating!that!metformin!leads!to!the!activation!of!the!LKB1!–!AMPK!axis.!!!Figure!taken!from!(Rattan!el!al.,!2012).!
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studied as either a sensitizer or an adjuvant to the current standard of treatment for 
specific cancers in non-diabetic patients. 
Since there has been a greater focus on metformin in breast cancer than any other 
cancer so far, the current theories and proposed treatment involving metformin for breast 
cancer will be presented, along with any conflicting viewpoints or observations in which 
metformin has shown no benefit. 
 Most of the current research in specific types of cancers is in the preclinical 
phase.  Breast cancer, however, has been given a much greater focus and has some 
clinical trials that are in motion (Litzenburger & Brown, 2014).  Metformin as an adjunct 
to chemotherapy is currently in some early stages of clinical trials for the treatment of 
breast cancer (Esteva et al., 2013).  The first clinical trial for metformin in the treatment 
of breast cancer was actually in 2011, and was a placebo vs. metformin neoadjuvant 
study for non-diabetic women during the preoperative period (Hadad et al., 2011).  
Metformin was also used in a couple other small scale neoadjuvant studies where it was 
given prior to surgery in women with breast cancer (Bonanni et al., 2012; Niraula et al., 
2012).  Some of the results from these studies found that metformin treatment in non-
diabetic patients supported the theory that it has an anti-neoplastic property, whereas one 
study showed that the effect of metformin treatment was not statistically significant 
overall in non-diabetic patients with breast cancer, but it was more effective for those that 
showed metabolic characteristics of a pre-diabetic (Bonanni et al., 2012; Niraula et al., 
2012). The sample sizes in these studies were small, so a larger scale study is needed in 
order to determine the efficacy of metformin with breast cancer.  Litzenburger & Brown 
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reported that there have been a few phase 1 and 2 clinical trials in recent years, and that 
phase 3 trials, which usually involve a greater subject population, are currently underway 
(Litzenburger & Brown, 2014).   
 Even though it will take some time for these clinical trials to run their course, the 
preclinical trials can still be looked at in order to determine which types of breast cancer 
metformin would be most effective in.  Some of the common characteristics that are 
looked at in describing the breast cancer type are the overexpression or lack thereof: 
estrogen receptor (ER), progesterone receptor (PR), or HER2 (also called erbB2) 
(Litzenburger & Brown, 2014).  When breast cancer lacks the expression of all three of 
these, then it is called a triple-negative breast cancer, which is more difficult to treat and 
occurs 15 – 20 % of the time (Litzenburger & Brown, 2014).   
 
 ER Positive 
 Breast cancer subtypes that overexpress ER and PR are more likely to have a 
better outcome with treatment and are at a lesser risk of tumor recurrence (Lippman, 
2012).  In addition to a better prognosis with current standard of care, Ma et al. and other 
studies have shown support of metformin’s efficacy in reducing cancer growth in ER 
positive cell lines (Alimova et al., 2009; Ma et al., 2014; Zhuang & Miskimins, 2008).  
An even more significant finding from Ma et al., however, was that metformin increased 
the efficacy of the drug tamoxifen (Ma et al., 2014).  A growing issue in the field of 
breast cancer is that some ER positive breast cancers cells are developing low sensitivity 
to tamoxifen treatment (Ma et al., 2014). This study has recently shown that tamoxifen 
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treatment in breast cancer xenograft mice acts synergistically with metformin to cause a 
more powerful inhibition of tumor growth in ER positive breast cancer, especially the 
ones with acquired resistance (Ma et al., 2014).  This shows that metformin either 
increases the sensitization of the cancer cell to tamoxifen and/or it has its own anti-
neoplastic properties.  Therefore the search for combination therapy has been of great 
interest to help increase efficacy of tamoxifen, and should be further explored in the case 
of other current standards of treatment. 
Endocrine therapies, like tamoxifen, are important in ER and PR positive types of 
breast cancer; however, they show little effect in ER negative breast cancers (Lippman, 
2012).  Instead, cytotoxic chemotherapy like the topoisomerase II inhibitor, doxorubicin, 
can be used for ER negative breast cancer cells, and will be discussed more in the triple 
negative breast cancer section (Chabner et al.,  2011).  
 
HER2 Positive 
The overexpression of human epidermal growth factor receptor 2 (HER2) is 
found in 30% of breast cancer cases and is due to gene amplification on chromosome 17 
(Chabner et al., , 2011b).  Alimova et al. observed reduced cell growth and increased cell 
cycle arrest with metformin treatment in many breast cancer cell lines, including ER 
positive and negative, and HER2 normal and overexpressing cell lines; however, this 
study focused more on the HER2 characteristic (Alimova et al., 2009).  Upon dosage 
with metformin in the HER2 overexpressing cell line, lower concentrations of 
phosphorylated erbB2/HER2 were observed using western blot analysis (Alimova et al., 
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2009). Since the phosphorylated form of HER2 is the active form, these data indicate that 
metformin reduces the activity of HER2 (Alimova et al., 2009).   
A similar study also observed inhibition of HER2 upon treatment with metformin, 
but took it a step further by giving evidence that the inhibition of HER2 was due to direct 
inhibition of an mTOR effector protein (Vazquez-Martin et al.,   2009).  This is great 
support for metformin’s role in treating HER2 cancers.  On the other hand, the authors in 
this study indicated that the molecular mechanism that produces this effect is independent 
of AMPK, which contradicts the previously mentioned mechanism of metformin.  This is 
a good example of the fact that the mechanism of action of metformin is still not entirely 
understood, despite the amount of research and time that has been put into this drug.  
Resistance to drugs targeting HER2 overexpressing cancer cell lines has also 
unfortunately become increasingly prevalent.  Trastuzumab, an antibody for the HER2 
external domain, is a common chemotherapeutic for HER2 positive breast cancer cells; 
however, trastuzumab resistant cancers have created a problem for treatment (Chabner et 
al., 2011b).  Searching for a drug to target these cells, researchers once again turned to 
metformin to determine if it proved to be efficacious here as well.  Liu et al. observed 
that trastuzumab resistant cancer cells undergo cellular changes that alter the normal 
molecular mechanisms of the cell, and that because of this, metformin is more effective 
in inhibiting tumorigenesis in these specific cells through the reduction of interaction 
between erbB2/HER2 and IGF1 (Liu et al., 2011, p. 2).  As complex as this may seem, it 
is further support for a potential use of metformin in yet another type of drug resistant 
breast cancer. 
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 Lastly, metformin was also studied for its effect on breast cancer stem cells, 
which display high expression of erbB2/HER2, and it is being increasing shown that 
these are the types of cells that are responsible for breast cancer initiation and 
development (Zhu et al., 2014).  It was found that metformin inhibited tumor formation 
of these breast cancer stem cells by interfering with the HER2, Akt, and mTOR pathways 
(Zhu et al., 2014). 
 
Triple Negative Breast Cancer 
 The type of breast cancer that is the most difficult to treat, with the poorest 
prognosis, is triple negative breast cancer, which lacks the ER, PR and HER2 receptors 
(Giuliano & Hurvitz, 2014).  Since hormone therapy proves to be unsuccessful for the 
treatment of this type, cytotoxic therapy is used instead, which is a toxic therapy with the 
purpose of killing the cancer cell (Giuliano & Hurvitz, 2014).  However, cytotoxic 
therapy also leads to the death of many normal human cells, usually the ones that undergo 
higher turnover.  Due to the problems associated with this type of breast cancer, a new 
drug that is effective and non-toxic for the treatment of triple negative breast cancer 
would be groundbreaking.  
 Along with the other various breast cancer subtypes, metformin is also being 
studied in the triple negative phenotype.  When studying 6 different breast cancer cell 
lines, Zhuang & Miskimins observed significant inhibition of growth in all the cell lines 
except for MDA-MD-231, which is a triple negative breast cancer cell line (Zhuang & 
Miskimins, 2008).  A different study further investigated the use of metformin in this 
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subtype of cancer cells by studying its affect on growth and proliferation in 4 different 
triple negative breast cancer cell lines, one of them being MDA-MD-231 (Liu et al., 
2009).  In vitro, all four cell lines showed tumor growth inhibition, but some of the lines 
required more of the drug that others to reach significant values (Liu et al., 2009).  Then 
an in vivo study using xenograft mice transplanted with MDA-MD-231 was performed 
and showed slower tumor growth and increased survival in the mice given metformin 
(Liu et al., 2009).  So, Zhuang & Miskimins presented data showing that metformin does 
not induce an antineoplastic effect in the MDA-MD-231 cell line, whereas Liu et al. did 
observe an antineoplastic effect in the MDA-MD-231 cell line (Liu et al., 2009; Zhuang 
& Miskimins, 2008).  The differing results from these two studies may be due to the 
difference in incubation time with metformin.  Zhuang & Miskimins measured growth 
after 3 days, whereas Liu et al. measured growth after 2-3 weeks (Liu et al., 2009; 
Zhuang & Miskimins, 2008). 
 An article published within the past year also studied the triple negative breast 
cancer cell line, MDA-MD-231, and reported data indicating that this cell line is sensitive 
to metformin treatment only at normal glycemic condition, and not at high glycemic 
conditions (Zordoky et al.,  2014).  This article suggests that something special about the 
molecular pathways in MDA-MD-231 enables normal glycemic levels to sensitize the 
cells to metformin treatment and inhibit growth (Zordoky et al., 2014).  The theory is that 
the metformin shows a significantly higher activation of AMPK at normal rather than 
high glucose levels (Zordoky et al., 2014). This is supported by the observation that high 
glucose levels downregulate AMPK in normal cells (Saha et al., 2011).  Lower AMPK 
!39 
levels would allow a smaller quantity of AMPK to respond to metformin.  These data 
suggest that normoglycemic patients with triple negative breast cancer similar to the 
MDA-MD-231 cell line would show better results with metformin treatment than patients 
with hyperglycemia.  
Even though cytotoxic therapy like doxorubicin is a toxic treatment, it is still 
effective sometimes in the treatment of triple negative breast cancer.  However, like other 
drugs, the cancer cells can acquire resistance to doxorubicin.  Hirsch et al. investigated 
this area of interest and observed that metformin worked synergistically with doxorubicin 
to kill the cancer cells, even in the triple negative breast cancer cell line (Hirsch et al.,  
2009).  They found that the cancer stem cells were more resistant to doxorubicin than the 
non-stem cell cancers (Hirsch et al., 2009). An important finding in this study, that is 
similar to findings of Zhu et al., is that metformin worked to preferentially kill the cancer 
stem cells, which the doxorubicin treatment struggled to kill (Hirsch et al., 2009).  As 
will be touched on in the discussion section, the concentrations required to observe an 
effect were crucial here.  Low concentrations of metformin showed an effect on the 
cancer stem cell populations; however, a significantly greater concentration was needed 
to observe an effect in the other cancer cells, which make up the majority of the 
cancerous tumor (Hirsch et al., 2009).  
  Given that there have been numerous articles investigating the potential of 
metformin in treating breast cancer, Table 3 displays some of the recently published 
findings of observed effects of metformin in various breast cancer subtypes and cell lines.  
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It is important to note which breast cancer subtypes have and have not been extensively 
studied in order to assess where it is most effective. 
 Combination therapy is also important for cancer therapy due to the resiliency of 
cancer cells.  Finding drugs with different mechanisms of action against a cancer cell 
give the best chance for an effective treatment.  The issue of overcoming drug resistant 
cancer cells is also becoming of utmost importance, and so the search for potential new 
antineoplastic agents is a major field of investigation.  Some of the current and recent 
publications involving metformin and an additive chemotherapeutic are displayed in 
Table 4. 
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Findings Publication Breast Cancer cell lines 
Vehicle 
of study 
Effective in ER+ breast 
cancer cell lines 
 
Alimova et al. 
2009 
ER+, HER2- 
(MCF7) In vitro 
Ma et al., 2014 
ER+, HER2- 
(MCF7) In vitro  
 ER+, HER2- 
(ZR-75-1) 
Zhuang & 
Miskimins, 2008 
ER+, HER2- 
(MCF7) In vitro 
Effective in HER2+ breast 
cancer cell lines 
 
Alimova et al., 
2009 
 
ER-, HER2 + 
(MCF7/713) 
In vitro 
 
ER+, HER2 + 
(Bt-474) 
ER-, HER2 + 
(SKBR-3) 
Vazques-Martin et 
al., 2009 
 
ER-, HER2 +  
(MCF-7/HER2) In vitro 
 ER-, HER2+  
(SKBR-3) 
Zhu et al., 2014 HER2+ (78617) 
In vitro 
and vivo 
Effective in stem cell breast 
cancer cells 
 
Hirsch et al., 2009 
Transformed Stem 
cells 
(MCF10A ER-
Src) 
In vitro 
Not effective in Triple 
Negative Breast Cancer cell 
line 
 
Zhuang & 
Miskimins, 2008 MDA-MD-231 In vitro 
Effective in Triple Negative 
Breast cancer cell lines 
 
B. Liu et al., 2009 
MDA-MB-468 
In vitro BT20 
BT549 
MDA-MB-231 In vitro and vivo 
Zordoky et al., 
2014 MDA-MB-231 In vitro 
Table'3:'Antineoplastic'effects'of'metformin'observed'in'various'breast'
cancer'cell'lines.''Some!of!the!significant!publications!in!this!area!of!study!that!are!leading!the!way!for!further!study!of!metformin!in!breast!cancer.!
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   Findings/Publication Breast Cancer cell line Vehicle of 
study 
Synergistic effect of metformin 
with doxorubicin  
 
Hirsch et al., 2009 
 
ER+, HER2- 
(MCF7) 
In vitro  
 
ER-, HER2+  
(SKBR3) 
Triple Negative  
(MDA-MB-486)  
Transformed Stem cells 
(MCF10A ER-Src) 
In vitro and 
vivo 
Synergistic effect of metformin 
with tamoxifen 
 
Ma et al., 2014 
 
ER+, HER2- 
(MCF7) 
In vitro 
ER+, HER2- 
(ZR-75-1) 
Synergistic effect of metformin 
with trastuzumab 
 
B. Liu et al., 2011 
BT474-HR20 
Trastuzumab resistant 
In vitro 
 
 SKBR3-pool3 
Trastuzumab resistant 
Table'4:'Synergistic'antineoplastic'effect'of'metformin'with'current'
cancer'therapeutics!in'breast'cancer'cell'lines.!!!
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DISCUSSION 
 
Metformin is one of the main choices of treatments for T2DM and has recently 
been proposed as a potential antineoplastic agent.  This was first suggested after 
epidemiology studies showed that metformin confers a significant reduction in cancer 
risk and mortality when compared to the other drugs for the treatment of T2DM.  Further 
investigation into the molecular mechanism of action allowed for an analysis of its effect 
on a cancer cell.  The knowledge of its indirect activation of AMP-activated protein 
kinase was very important in elucidating the proposed link between metformin and 
inhibition of cell cycle and proliferation.  However even after all these years of research 
on metformin’s mechanism of action, it is still not fully understood due to the fact that 
many publications show contradictions or new unexplored mechanisms.   
Some of the major mechanisms of metformin’s antineoplastic effects are mediated 
through the cyclin/CDKS and mTOR pathways.  Metformin causes AMPK activation, 
which then proceeds to reduce cyclin D1 levels and allow the CDK inhibitors, p27 and 
p21 to inhibit cyclin E/CDK2 (Zhuang & Miskimins, 2008).  The reduced activity from 
this cyclin/CDK complex leads to the inability to inactivate the tumor suppressor pRB, 
and therefore pRB causes arrest in G1 phase.  A major implication that can be taken from 
this study is that metformin may not be effective if the cancer cell expresses low or 
depleted levels of p21 and p27.  Also it important to understand that metformin halts the 
cell cycle by a p53 independent pathway, which was confirmed by a study that showed 
that metformin suppressed tumor growth in a colon cancer cell line deficient in p53 
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(Buzzai et al., 2007)  This is a significant finding since p53 is usually one of the 
mutations that a cell needs to acquire in order to become cancerous. 
The other major mechanism discussed was the inhibition of mTOR via activation 
of AMPK.  This was determined from the observation of decreased phosphorylated S6 
after metformin treatment.  An activated mTOR will phosphorylate S6, so their findings 
show that metformin acts to inhibit mTOR (Cantrell et al., 2010).  The mTOR pathway is 
a commonly up-regulated in cancer cells and it is involved in promoting proliferation, 
growth, angiogenesis, and metabolism (Lake et al., 2012).  Therefore the finding that 
metformin decreases mTOR signaling is in strong favor of its antineoplastic capabilities. 
As the antineoplastic properties of metformin became increasingly evident, 
researchers started to look for its efficacy in specific cancer types.  Initially, metformin 
was studied the most for its efficacy in breast cancer.  Various breast cancer cell lines 
were tested and helped elucidate some further support of its mechanism of action.  Of the 
breast cancer subtypes, metformin was shown to have some efficacy in reducing cancer 
growth in the ER positive, HER2 positive, and even the triple negative phenotypes.  Its 
efficacy on the HER2 positive cancer cells, which have an overexpression of HER2, was 
found to be due to metformin’s ability to reduce the mTOR signaling pathway.  However, 
as mentioned previously, researchers studying the same cells and pathways sometimes 
receive different results.  One study reported that metformin’s inhibition of the HER2 
positive cancer cells was due to an AMPK independent mechanism (Vazquez-Martin et 
al., 2009).  Thus it is important to realize that the cellular pathways involved in growth, 
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proliferation, and metabolism are extremely complex, and that one drug may have 
numerous effects on the cell.   
It is more important to realize, however, that a drug at extremely high 
concentration will begin to show effects on many more pathways than seen from in vivo, 
where the concentration is usually significantly lower. A criticism of one metformin 
study described that the concentrations used to study metformin’s effects on cancer cells 
in vitro were 100 to 1000 times the blood plasma concentration seen in humans at a 
normal dosage (Stambolic et al., 2009).  This criticism of one study can be applied to 
many of the studies that have published results in support of metformin’s effect on 
inhibiting tumorigenesis.  One study that used concentrations of metformin closer to the 
clinically accepted levels did not find any effect of metformin on multiple subtypes of 
breast cancer (Sadighi et al., 2014).  However, some studies have shown efficacy with 
metformin at a lower concentration (Ma et al., 2014; Zordoky et al., 2014).  Thus this 
issue should not destroy the initiative for metformin usage in cancer, but it suggests that 
more attention should be paid to clinically relevant dosage in preclinical studies.  It also 
suggests that metformin may best play a part in cancer treatment as an additional therapy 
to the current standards of treatment.  Due to its non-toxic nature, it would not add to the 
gruesome side effects of the toxic chemotherapy.  Therefore preclinical studies may find 
greater success when studying metformin at low doses in combination with currently 
prescribed chemotherapeutics for their synergistic effect on tumor growth.  On the other 
hand, since the dosage of metformin used for the treatment of T2DM results in a plasma 
level that is relatively safe and nontoxic, it may be beneficial to raise the accepted plasma 
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level that is allowed for use in humans.  This will require pharmacokinetics studies in 
order to determine the point at which metformin starts showing adverse side effects. 
As metformin has shown to be of some usefulness in breast cancer, it has recently 
passed phase 1 and 2 clinical trials and is currently in the 3rd stage of testing 
(Litzenburger & Brown, 2014).  Due to the large push for metformin use in breast cancer, 
many researchers have thus decided to look at metformin in other types of cancer.  Li et 
al. are looking at the use of metformin as an adjunctive treatment in resistant subtypes of 
lung cancer (Li et al., 2014).  Honjo et al. has observed that metformin sensitizes 
esophageal tumors to 5-fluorouracil treatment, improving outcome (Honjo et al., 2014). 
Metformin was also shown to act synergistically with 5-fluorouracil and oxaliplatin for 
the treatment of recurrent colorectal cancer (Nangia-Makker et al., 2014). Lastly, due to 
metformin’s independence of the p53 pathway, it is currently under consideration for the 
use as a cancer therapeutic in patients with Li-Fraumei syndrome, which is caused by 
germline mutations in the p53 gene (Sorrell et al.,  2013). The role of metformin as an 
adjunctive therapy to the current standard of treatments is a growing area of research, 
which may prove to be an effective combination therapy for a diverse set of cancer types.   
Another area of interest that has recently developed is the use of a metformin 
derivative in the treatment of cancer (Koh et al., 2013).  Koh et al. synthesized a 
derivative of metformin that showed greater efficacy in the treatment of a triple negative 
breast cancer cell line than the original metformin formulation (Koh et al., 2013).  Often 
new drug formulations are made in order to increase efficacy or decrease toxicity.  Koh et 
al. may have discovered a better formulation than the original substance, metformin, 
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which has proven to be of great potential for cancer treatment.  However, until either of 
these two drugs’ potentials can be fulfilled, many years of ongoing research will still be 
needed.  Preclinical trials in various types of cancer should be performed in order to 
maximize the usage of metformin, and perhaps the new derivative.  Lastly, at the end of 
all the meticulous research, only large scale clinical trials will be the determining factor 
for whether or not metformin will be shown to be efficacious for the treatment of cancer, 
whether as a single or combination therapy. !! !
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